CALL FOR ABSTRACTS

• Cytotoxics and Other Novel Therapeutics (Non-IO, Non-Targeted)
  Keywords: Cytotoxic Chemotherapy, Antibody Drug Conjugates, Novel Ablative Therapy
• Diagnostics and Interventional Pulmonology
  Keywords: Diagnostic Radiology, Computed Tomography, Positron Emission Tomography–Computed Tomography, Interventional Radiology, Bronchoscopy, Pleuroscopy
• Early Stage/Localized Disease
  Keywords: Induction, Neoadjuvant, Adjuvant, Early Stage, Minimally Invasive Surgery, Stage I, Stage II
• Health Services Research/Health Economics
  Keywords: Health Policy, Cost Effectiveness, Quality of Care, Reimbursement, Healthcare Access, Qualitative Research, Economic Evaluation, Real-World Data, Observational Cohort Studies, Electronic Health Records, Disease Registries And Databases, Billing Databases
• Immuno-Biology and Novel Immunotherapeutics (Phase I and Translational)
  Keywords: Tumor Micro-environment, Bi-specific Ab, Vaccine Therapy, Cellular Therapy, Chimeric Antigen Receptors, Viroimmunotherapy, Cytokine Therapy, Translational Research, Check-Point Blockade Beyond PD-1/L1
• Immunotherapy (Phase II/III Trials)
  Keywords: Phase II and III Clinical Trials, Immune Checkpoint Inhibitors, Randomised Controlled Trials
• Locoregional and Oligometastatic Disease
  Keywords: Stereotactic Body Radiotherapy, Stereotactic Ablative Radiotherapy, Local Ablative Therapy, Stage III, Combined Modality Treatment
• Mesothelioma, Thymoma and Other Thoracic Malignancies
  Keywords: Malignant Mesothelioma, Thymoma, Thymic Carcinoma, Thymic Epithelial Tumors, Oesophageal Cancer
• Nursing and Allied Health Professionals
  Keywords: Rehabilitation, Physiotherapy, Nursing Care, Psychology
• Palliative and Supportive Care
  Keywords: Palliative care, Decision-making, Communication, Decision Support Techniques, Ethics, Quality of Life
• Pathology, Molecular Pathology and Diagnostic Biomarkers
  Keywords: Pathology, FISH, Histology, Immunohistochemistry, Cytology, Molecular Pathology, Biomarkers, Circulating Tumor Cells, Circulating Tumor DNA, Cell Free DNA, Circulating Cell-Free Noncoding RNAs, Circulating Exosomes, Liquid Biopsy
• Patient Advocacy (Information for submitters to patient advocacy track) 
  Keywords: Survivorship, Advocacy, Community Outreach, Patient-driven Research, Advocacy Foundations, Patient Advocacy, Patient Reported Outcomes
• Risk Reduction and Tobacco Control
  Keywords: Tobacco Control Policy, Tobacco Prevention Patient, Framework Convention on Tobacco Control, Smoking Cessation, Radon, Bio Mass, Environmental
• Screening and Early Detection
  Keywords: Screening, Early Detection, Low Dose Spiral CT Scan, Early Diagnosis, Exhaled Air, Pulmonary Nodule, GGO, Biomarkers For Early Detection, Risk Models, Nodule Evaluation, Artificial Intelligence For Early Detection
• Staging
  Keywords: Staging, Tumor Size Characteristics, Node Characteristics, Metastatic Characteristics, IASLC Staging System
• Small Cell Lung Cancer/NET
  Keywords: Small Cell Lung Cancer, Neuroendocrine Tumours, Atypical Carcinoid
• Tumor Biology and Systems Biology – Basic and Translational Science
  Keywords: Tumor Biology, Mouse Models, Basic Science, Translational Science, Bioinformatics, Artificial Intelligence, Machine Learning, Transcriptomics, Radiomics
• Targeted Therapy – Clinically Focused
  Keywords: Tyrosine Kinase Inhibitors, Targeted Therapies, Driver Oncogenes, NGS in the Context of Clinical Trials

Regular Abstract
Definition: Original scientific research that summarizes work done and major research findings.

Required sections for abstract submission:

• Introduction
• Methods
• Results
• Conclusion

Clinical Trials in Progress
Definition: Ongoing trials that have not reached pre-specified endpoints for analysis.

Required sections:

• Introduction
• Methods

Optional sections:

• Results
• Conclusion

Case Report (eligible for designation as a poster or e-poster only)
Definition: Detailed report of symptoms, signs, diagnosis, treatment and follow up of an individual patient.

Required sections for abstract submission:

• Introduction
• Methods
• Results
• Conclusion

Late-Breaking Abstract (LBA) Submission
Definition: LBA designation will only be given to clinically relevant prospective studies in which data is not available at the time of abstract placeholder submission due to study timelines.

LBA designation is not a means for extending the regular abstract deadline. Any abstract that fails to meet LBA requirements will be designated as a regular abstract and rated based on the information available on the submission deadline.

Submission requirements: Authors of LBA must submit a place holder abstract through the abstract portal by August 28, 2020 (23:59 PST).

Required sections for place holder abstracts:

• Explanation of why the abstract qualifies as late breaking
• Introduction
• Methods, including endpoints measured
• Types of analysis and anticipated data reporting
• Results and conclusion will be submitted later

Review: The Scientific Program Committee will review LBA abstract placeholder applications. Authors of approved LBAs will be notified and instructed on deadlines and processes for submitting final data.

Encore Submission: An abstract that has previously been presented at another meeting will only be considered if there have been significant updates to the abstract. Submitters are required to list any previous abstracts in the introduction of the abstract.

Author Information and Affirmations 

• Financial disclosure and affiliation information is required for all authors/coauthors. The submitting author may enter co-author disclosure information. Use this link to access a fillable financial disclosure form that can be used to collect this information from co-authors.
• Publication:Authors must agree to allow publication of accepted abstract(s) in the Journal of Thoracic Oncology (JTO) and the conference website prior to the meeting, except for embargoed abstracts which will be posted the day of presentation.

Travel and Mentorship Awards
These awards are presented to individuals with high scoring abstracts who meet categorical eligibility criteria and who apply. Applications must be completed by the abstract submission deadline.

Independence of Educational Activities Policy 

• Employees of ACCME defined commercial interests are prohibited from presenting educational content for Continuing Medical Education. Abstracts submitted by employees of commercial interests will only be considered for poster or e-posters.
• Presenting author must control all content. Commercial interests may not influence scientific content by requiring the use of company slide decks or other materials. Scientific data generated by industry sponsored research is permissible.
• Content of educational activities must be well-balanced, evidence based and unbiased. Generic names should be used to the extent possible.

Plagiarism Policy

• Definition: Plagiarism encompasses all of following:
  1. Direct: intentionally submitting another person’s words or ideas verbatim as one’s own;
  2. Self-plagiarism: submitting work that has been previously published or presented;
  3. Mosaic plagiarism: stringing together portions of text from other sources; and
  4. Lack of attribution: failing to appropriately identify and cite sources for language or ideas that are incorporated.
  For more information see: Das N, Panjabi M. Plagiarism: Why is it such a big issue for medical writers? Perspect Clin Res. 2011;2(2):67–71. doi:10.4103/2229-3485.80370 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3121267/ 

• Screening: IASLC screens all abstracts using anti-plagiarism software. Abstracts identified as having high levels of plagiarized content will be evaluated by IASLC staff and appropriate actions taken.

• Penalties for plagiarism may include: Rejection of abstract, and/or author(s) banned from making presentations at IASLC conferences.

When will the Peer Review and Late-Breaking abstract titles and abstract body be published online?
January 12, 2021 (15:00 PST)

Does WCLC accept abstracts that have been submitted and presented to a previous Congress (ie, encore abstracts, trials in progress encore abstracts)?
An abstract that has previously been presented at another meeting will only be considered if there have been significant updates to the presentation. Submitters are required to list any previous presentations in the introduction of the abstract.

Are case reports/case series considered for presentations?
Yes, we do allow the submission of case reports.

What is the withdraw deadline for regular submissions and late breaking submissions?
Presenting author registration deadline is December 11, 2020. Any abstract presenters not registered by this date, their abstracts may be withdrawn from the program.

For late-breaking abstracts, does the congress only permit abstracts that report on Phase 3 [and higher] studies?
There are no guidelines/regulations as to which trials or studies can apply for late breaking privileges. We do not restrict late breaking privileges to ‘reports on Phase 3 (and higher) studies’.

Could I send my manuscript to publish to a journal in my country before WCLC?
If the abstract is published in a journal before WCLC, the publication may affect the abstract rating. There are no rules preventing submitters from publishing their abstract in a journal before WCLC.

Is industry allowed to be in lead or senior author positions on the author list for WCLC abstract submissions? Are there restrictions towards pharmaceutical/commercial authors on presenting abstracts at the meeting?
Yes, industry is permitted to be in the lead and senior author positions in the author list of an abstract. Industry/pharmaceutical/commercial authors are prohibited from presenting Oral and Mini Oral presentations. Industry/pharmaceutical/commercial authors are permitted to present poster presentations.

Would it be possible to submit an abstract without results and conclusion?
You must submit a placeholder abstract by August 28, 2020. Please note abstracts submitted without results and conclusion may affect the rating of the abstract.

Is there a limit on the number of abstracts in which an author can be lead author?
There is no limit to the number of abstracts in which an author can be lead author. An individual may not be offered more than 2 oral presentations.

Is there any charge for the submission of abstracts, and if so, how much is it?
No, there is no charge to submit an abstract to WCLC.

For inquiries, please contact [email protected]. If your inquiry is regarding a particular draft or submission, please include the abstract ID in your email.